title: Patterns of brain glucose metabolism induced by phosphodiesterase 10A inhibitors in the mouse: a potential translational biomarker.
abstract: Phosphodiesterase 10A (PDE10A) inhibitors have recently been proposed as a new therapy for schizophrenia. The aim of this study was to enhance our understanding of the role of PDE10A inhibitors and potentially identify a clinically useful mechanistic/functional biomarker by using 2-deoxyglucose (2-DG) autoradiography. PDE10A inhibitors papaverine (10 and 40 mg/kg), 6,7-dimethoxy-4-[(3R)-3-(2-quinoxalinyloxy)-1-pyrrolidinyl]quinazoline (PQ-10), (0.16-10 mg/kg), and 2-[{4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy}methyl]quinoline (MP-10) (0.16-40 mg/kg) induced region-specific hypermetabolism in the globus pallidus and lateral habenula of C57BL/6 mice. Studies with MP-10 revealed a dose-dependent relative increase in globus pallidus activation, whereas a bell-shaped curve was observed for the lateral habenula. Although the relative increase in 2-DG uptake in the lateral habenula was also characteristic of the D(2) antagonist haloperidol (0.01-0.63 mg/kg), relative 2-DG changes were absent in the globus pallidus. This observation probably is explained by the interaction of PDE10A inhibitors with the D(1) direct pathway as suggested by experiments in combination with the D(1) agonist (±)-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (SKF-82958) (0.16 mg/kg). The absence of an effect of MP-10 (2.5 mg/kg) on relative glucose metabolism in the globus pallidus and lateral habenula of PDE10A knockout mice confirmed the specificity of the signal induced by PDE10A inhibitors. These studies substantiate the regulatory role of PDE10A in the basal ganglia circuit and as such support the potential of PDE10A inhibitors for treating psychiatric disorders. Moreover, we could differentiate PDE10A inhibitors from haloperidol based on specific patterns of hypermetabolism probably caused by its combined action at both direct and indirect dopaminergic pathways. Finally, these specific changes in brain glucose metabolism may act as a translational biomarker for target engagement in future clinical studies.
authors: Department of Translational Neuroscience and Molecular Imaging Center, University of Antwerp, Antwerp, Belgium.
authors: Stefanie
authors: S
authors: Dedeurwaerdere
authors: Cindy
authors: C
authors: Wintmolders
authors: Greet
authors: G
authors: Vanhoof
authors: Xavier
authors: X
authors: Langlois
mesh_terms: D000818:Animals; D000963:Antimetabolites; D014150:Antipsychotic Agents / Q000494:pharmacology; D001345:Autoradiography; D001552:Benzazepines / Q000494:pharmacology; D015415:Biomarkers / Q000032:analysis; D001923:Brain Chemistry / Q000187:drug effects*; D003720:Densitometry; D003847:Deoxyglucose; D018491:Dopamine Agonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005947:Glucose / Q000378:metabolism*; D006220:Haloperidol / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010208:Papaverine / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D010727:Phosphoric Diester Hydrolases / Q000235:genetics / Q000378:metabolism*; D046188:Protein Modification, Translational / Q000187:drug effects
chemical_list: D000963:Antimetabolites; D014150:Antipsychotic Agents; D001552:Benzazepines; D015415:Biomarkers; D018491:Dopamine Agonists; D010726:Phosphodiesterase Inhibitors; C071262:SK&F 82958; D003847:Deoxyglucose; D010208:Papaverine; C492284:Pde10a protein, mouse; D010727:Phosphoric Diester Hydrolases; D005947:Glucose; D006220:Haloperidol